Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totaling 54,453 shares, a drop of 38.9% from the June 30th total of 89,082 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average trading volume of 45,733 shares, the days-to-cover ratio is currently 1.2 days.

Estrella Immunopharma Stock Down 4.4%

Shares of ESLA traded down $0.03 during trading hours on Thursday, reaching $0.74. 26,234 shares of the company traded hands, compared to its average volume of 116,042. The business has a fifty day moving average price of $0.98 and a 200-day moving average price of $1.16. Estrella Immunopharma has a 12-month low of $0.69 and a 12-month high of $3.15. The stock has a market capitalization of $32.06 million, a P/E ratio of -2.19 and a beta of 0.85.

Estrella Immunopharma (NASDAQ:ESLA) last issued its earnings results on Saturday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. As a group, research analysts predict that Estrella Immunopharma will post -0.29 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Estrella Immunopharma has an average rating of “Hold” and an average price target of $8.00.

Institutional Investors Weigh In On Estrella Immunopharma

A number of large investors have recently bought and sold shares of the company. Quadrature Capital Ltd acquired a new position in Estrella Immunopharma in the 4th quarter worth approximately $43,000. State Street Corp grew its holdings in Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after acquiring an additional 20,900 shares during the period. XTX Topco Ltd grew its holdings in Estrella Immunopharma by 376.9% during the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after acquiring an additional 39,099 shares during the period. Marshall Wace LLP acquired a new position in Estrella Immunopharma in the fourth quarter valued at approximately $88,000. Finally, Geode Capital Management LLC boosted its position in Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after purchasing an additional 8,318 shares in the last quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.